Naloxone HCl Dihydrate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563433

CAS#: 51481-60-8

Description: Naloxone HCl Dihydrate is a specific opiate antagonist. It acts by being competitive at mu, delta, and kappa opioid receptors.

Price and Availability

Size Price Shipping out time Quantity
250mg USD 330 2 Weeks
1g USD 770 2 Weeks
5g USD 1960 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-09. Prices are subject to change without notice.

Naloxone HCl Dihydrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 563433
Name: Naloxone HCl Dihydrate
CAS#: 51481-60-8
Chemical Formula: C19H26ClNO6
Exact Mass:
Molecular Weight: 399.86
Elemental Analysis: C, 57.07; H, 6.55; Cl, 8.87; N, 3.50; O, 24.01

Synonym: Naloxone Hydrochloride Dihydrate; Naloxone HCl Dihydrate; Naloxone HCl 2H2O;

IUPAC/Chemical Name: (4R,4aS,7aS,12bS)-3-allyl-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one hydrochloride dihydrate


InChi Code: InChI=1S/C19H21NO4.ClH.2H2O/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;;;/h2-4,14,17,21,23H,1,5-10H2;1H;2*1H2/t14-,17-,18+,19-;;;/m1.../s1

SMILES Code: O=C1[C@@H]2[C@]34C5=C(O2)C(O)=CC=C5C[C@@H](N(CC=C)CC4)[C@]3(O)CC1.[H]Cl.[H]O[H].[H]O[H]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Chen X, Wang L, Fan S, Song S, Min H, Wu Y, He X, Liang Q, Wang Y, Yi L, Gao Q. Puerarin acts on the skeletal muscle to improve insulin sensitivity in diabetic rats involving μ-opioid receptor. Eur J Pharmacol. 2018 Jan 5;818:115-123. doi: 10.1016/j.ejphar.2017.10.033. Epub 2017 Oct 20. PubMed PMID: 29061371.

2: Dai W, Xiao D, Gao X, Zhou XB, Fang TY, Yong Z, Su RB. A brain-targeted ampakine compound protects against opioid-induced respiratory depression. Eur J Pharmacol. 2017 Aug 15;809:122-129. doi: 10.1016/j.ejphar.2017.05.025. Epub 2017 May 11. PubMed PMID: 28502631.

3: Janas A, Folwarczna J. Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis. Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):175-185. doi: 10.1007/s00210-016-1295-6. Epub 2016 Nov 28. PubMed PMID: 27896372; PubMed Central PMCID: PMC5233738.

4: Flint M, Than JT. Potential spawn induction and suppression agents in Caribbean Acropora cervicornis corals of the Florida Keys. PeerJ. 2016 Apr 26;4:e1982. doi: 10.7717/peerj.1982. eCollection 2016. PubMed PMID: 27168990; PubMed Central PMCID: PMC4860313.

5: Ruetzler K, Blome CJ, Nabecker S, Makarova N, Fischer H, Rinoesl H, Goliasch G, Sessler DI, Koinig H. A randomised trial of oral versus intravenous opioids for treatment of pain after cardiac surgery. J Anesth. 2014 Aug;28(4):580-6. doi: 10.1007/s00540-013-1770-x. Epub 2013 Dec 28. PubMed PMID: 24375220.

6: Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry. 2013 Dec;70(12):1347-54. doi: 10.1001/jamapsychiatry.2013.2216. PubMed PMID: 24153411; PubMed Central PMCID: PMC4131728.

7: Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011 Mar 14;171(5):425-31. doi: 10.1001/archinternmed.2010.541. PubMed PMID: 21403039; PubMed Central PMCID: PMC3059544.

8: Mostafavi A, Abedi G, Jamshidi A, Afzali D, Talebi M. Development and validation of a HPLC method for the determination of buprenorphine hydrochloride, naloxone hydrochloride and noroxymorphone in a tablet formulation. Talanta. 2009 Feb 15;77(4):1415-9. doi: 10.1016/j.talanta.2008.09.024. Epub 2008 Sep 24. PubMed PMID: 19084658.

9: Rizzo A, Minoia G, Ceci E, Manca R, Mutinati M, Spedicato M, Sciorsci RL. The effect of calcium-naloxone treatment on blood calcium, beta-endorphin, and acetylcholine in milk fever. J Dairy Sci. 2008 Sep;91(9):3454-8. doi: 10.3168/jds.2007-0838. PubMed PMID: 18765603.

10: Berrocoso E, De Benito MD, Mico JA. Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. Psychopharmacology (Berl). 2007 Jul;193(1):97-105. Epub 2007 Mar 29. PubMed PMID: 17393145.

11: Santos AR, Miguel OG, Yunes RA, Calixto JB. Antinociceptive properties of the new alkaloid, cis-8, 10-di-N-propyllobelidiol hydrochloride dihydrate isolated from Siphocampylus verticillatus: evidence for the mechanism of action. J Pharmacol Exp Ther. 1999 Apr;289(1):417-26. PubMed PMID: 10087033.

12: Yamamoto M, Shimizu M, Okamiya H. Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia. Eur J Pharmacol. 1990 Jun 8;181(3):207-14. PubMed PMID: 2116971.

13: Yamamoto M, Shimizu M, Ozawa Y. Effects of YM-14673, a new TRH analogue, on responses to morphine in rodents. Arch Int Pharmacodyn Ther. 1989 Jul-Aug;300:29-36. PubMed PMID: 2515820.

14: Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther. 1988 Feb;244(2):501-7. PubMed PMID: 3346833.

15: Kuriyama K, Tomono S. Significance of the enhancement of GABA receptor binding with low affinity in the assessment of central effects of benzodiazepine derivatives: Analysis using a 1H-1,2,4-triazolyl benzophenone derivative (450191-S). Neurochem Int. 1986;9(1):91-8. PubMed PMID: 20493105.

16: Woods JH, Young AM, Medzihradsky F, Smith CB, Aceto MD, Harris LS, Jacobson AE. Zomepirac: preclinical narcotic abuse liability evaluation. Arzneimittelforschung. 1983;33(2):218-22. PubMed PMID: 6133523.